• Vaccine Capacity Musical Chairs

    In the past six months, I’ve spoken to more vaccine developers than I have in the previous eight years, all of them searching for production capacity. With the good news from Pfizer, Moderna, and many other organizations completing their clinical trials and vaccine production, and distribution being maybe only weeks away, does this mean the music has stopped and it is time to grab a chair?

  • Art And Science Of Tech Transfer — Establishing The Path For Success

    Pharmaceutical technology transfer often invokes images of a complicated set of activities required to transfer the development and manufacturing of a product, or products, from one facility to another. This article shares five features of a successful tech transfer, imperatives that we have learned with a focus on drug sponsors working with CDMOs. These imperatives, when applied to project management operations, can deliver extraordinary results.

  • Residual Host Cell DNA Quantitation: In-House Vs. Commercial

    Here, we illustrate approaches for analytical method development and the challenges that may be encountered, particularly in the development of a quantitative assay for residual host cell DNA.  

  • Quantification Of Vector Genomic, Residual DNA In Gene Therapy Vectors

    Bringing cell and gene therapy drugs to market requires improvement in many areas, including analytical testing methods, which are used to determine the safety, strength, and purity of viral vectors.

  • Sterile Parenteral, Aseptic Fill-Finish, Helping You Take Your Drug from Concept To Clinical To Commercial

    Pii can provide you with the state-of-the-art GENiSYS R aseptic filling and closure system. The GENiSYS R aseptic filling and closure system is a fully robotic, automated line providing accurate precision-filling and eliminating the loss of costly drug product.


  • Surfactant Analysis Services

    Successful drug product development should integrate formulation, manufacturing process, primary packaging, device and delivery to the patient. Lonza’s Drug Product Services (DPS) offering delivers a holistic approach to DP development that anticipates and prevents problems early, and ensures the result is a product that is fit for purpose.

  • Light Path™ Custom Material Supply: Mammalian And Microbial Custom Services For Protein Production

    At Lonza, we understand the challenges facing biotherapeutic and vaccine manufacturers related to the time and costs inherent in the drug discovery and development process. Light Path™ Custom Material Supply Services are efficient, focused technology and production offerings for the Preclinical and Phase I stages of novel biologics development.

  • Singota Solutions – Your CDMO Focused On Faster

    Do you need a contract development and manufacturing organization (CDMO) that will fill the gaps in the drug development process and focus on getting patients the treatments they need faster? Read how the team of experts at Singota is here to collaborate with you, customizing our services to meet your needs and hit your milestones.

  • IDT Biologika - A Viral Vaccine And Viral Vector CDMO

    IDT Biologika provides contract development and manufacturing of live viral vaccines, gene and immune therapeutics, and fill/finish of biologics.

  • OnTheGoSM Services Fact Sheet

    OnTheGoSM is a PDMA-compliant suite of mobile/web apps that optimize sales representative productivity and enhance practitioner convenience and service. They complement the Patheon, by Thermo Fisher Scientific specialty logistics sample distribution service offering by providing Sales Representatives and Managers with enhanced capabilities.